Bone is the most frequently targeted site for PCa metastasis as opposed to soft tissues site. The reason for this selectivity is unknown but the bone microenvironment, including osteoblast and osteoclast activity, have been show to promote PCa growth. Osteocytes (OCys), which respond to pressure through mechanotransduction, are the most common cell in bone (>90% of bone cells). However, the role of OCys in progression of PCa bone metastasis has not been elucidated. We have now identified that PCa cells, through soluble factors, educate OCys to produce Growth differentiation factor 15 (GDF15), which stimulates PCa cell invasion and growth. We further identified that PCa cells express the novel GDF-15 receptor, GDFN family receptor alpha-like precursor (GFRAL), which has not been explored in cancer and thus, how it contributes to metastasis is a gap of knowledge. In addition to directly targeting the PCa cells, GDF15 has been shown to target the microenvironment and induce osteoclast (OCl) production and subsequent bone resorption which can promote seeding and growth of PCa in bone and we identified that osteoclasts express GFRAL. Furthermore, we previously identified that the bone microenvironment confers a chemoresistant phenotype to bone and have preliminary data suggesting that the GDF15:GFRAL contributes to the phenotype. Taken together, these findings lead us to hypothesize that PCa-educated OCys promote PCa bone metastasis through the GDF15:GFRAL axis. We will explore this hypothesis through the following aims:
Aim 1. Determine the role of GFRAL signaling on cellular function in PCa bone metastasis.
Aim 2. Determine if OCys promote bone metastasis through GDF15:GFRAL axis activation of osteoclasts.
Aim 3. Identify mechanisms through which GFRAL promotes chemoresistance in bone. We believe these studies will provide a new understanding of the role of OCys and GFRAL in PCa bone metastasis and identify novel therapeutic targets.

Public Health Relevance

Prostate cancer (PCa) is the most common cancer of American men and the second leading cause of cancer- related death most often due to bone metastasis. This project will explore how the cancer changes the bone environment so that it becomes conducive to bone metastasis. This will help identify targets to prevent or treat bone metastasis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA093900-16
Application #
9935669
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2020-06-01
Budget End
2021-05-31
Support Year
16
Fiscal Year
2020
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Hill, Elliott E; Kim, Jin Koo; Jung, Younghun et al. (2018) Integrin alpha V beta 3 targeted dendrimer-rapamycin conjugate reduces fibroblast-mediated prostate tumor progression and metastasis. J Cell Biochem 119:8074-8083
Axelrod, Haley D; Valkenburg, Kenneth C; Amend, Sarah R et al. (2018) AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer. Mol Cancer Res :
de Groot, Amber E; Pienta, Kenneth J (2018) Epigenetic control of macrophage polarization: implications for targeting tumor-associated macrophages. Oncotarget 9:20908-20927
Roca, Hernan; Jones, Jacqueline D; Purica, Marta C et al. (2018) Apoptosis-induced CXCL5 accelerates inflammation and growth of prostate tumor metastases in bone. J Clin Invest 128:248-266
Wu, Amy; Liao, David; Kirilin, Vlamimir et al. (2018) Cancer dormancy and criticality from a game theory perspective. Cancer Converg 2:1
Park, Sun H; Keller, Evan T; Shiozawa, Yusuke (2018) Bone Marrow Microenvironment as a Regulator and Therapeutic Target for Prostate Cancer Bone Metastasis. Calcif Tissue Int 102:152-162
Singhal, Udit; Wang, Yugang; Henderson, James et al. (2018) Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Mol Cancer Res 16:643-654
Lee, Eunsohl; Wang, Jingcheng; Jung, Younghun et al. (2018) Reduction of two histone marks, H3k9me3 and H3k27me3 by epidrug induces neuroendocrine differentiation in prostate cancer. J Cell Biochem 119:3697-3705
van der Toom, Emma E; Axelrod, Haley D; de la Rosette, Jean J et al. (2018) Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies. Nat Rev Urol :
Roca, Hernan; McCauley, Laurie K (2018) Efferocytosis and prostate cancer skeletal metastasis: implications for intervention. Oncoscience 5:174-176

Showing the most recent 10 out of 228 publications